Warsaw, IN, July 18, 2025 – Zimmer Biomet Holdings, Inc., a leading innovator in medical technology, has announced a definitive agreement to acquire Monogram Technologies, an orthopedic robotics company, in a transaction valued at approximately $177 million. Under the terms of the agreement, Monogram stockholders will receive an upfront cash payment of $4.04 per share and a contingent value right (CVR) of up to $12.37 per share, tied to regulatory and product development milestones through 2030.

The acquisition enhances Zimmer Biomet’s ROSA® Robotics platform by integrating Monogram’s AI-powered total knee arthroplasty (TKA) robotic technology. The deal positions Zimmer Biomet as the first orthopedic company to offer a fully autonomous surgical robotic system, delivering next-generation capabilities to support diverse surgical techniques and preferences.

Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, stated, “Monogram’s technology reinforces our commitment to innovation in surgical navigation and robotics. This acquisition accelerates our vision of a comprehensive, flexible technology ecosystem that meets every surgeon’s unique needs while paving the way for fully autonomous orthopedic procedures.”

The boards of directors from both companies have approved the transaction, which is expected to close following customary regulatory approvals.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com